Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma (KAPA) reported new equity awards and bonuses. On October 8, 2025, the Compensation Committee approved an aggregate $950,000 in restricted stock units (RSUs) under the 2023 Equity Incentive Plan for executive officers and directors, calculated at a per share price of $1.31 (the closing price on the grant date). Awards include: John S. Yu 190,840 RSUs valued at $250,000; Neil Bhomick 171,756 RSUs valued at $225,000; Ramachandran Murali 152,672 RSUs valued at $200,000; Doug Samuelson 152,672 RSUs valued at $200,000. Independent directors Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Singhvi each received 19,084 RSUs valued at $25,000.
Each RSU converts into one share upon vesting on October 8, 2026, subject to continuous service, with full acceleration upon a change in control as defined in the Plan. The Committee also approved executive cash bonuses totaling $227,500 for fiscal 2024: Yu $87,500; Bhomick $50,000; Murali $40,000; Samuelson $50,000. The shares underlying these RSUs are registered on Form S-8.
Kairos Pharma, Ltd. reported that its board approved two novation agreements that move key license rights from its wholly owned subsidiary Enviro Therapeutics, Inc. directly to Kairos. Under a novation with Cedars-Sinai Medical Center, the exclusive licenses for two patent families covering DNA-based disease treatments and tumor sensitization technologies are now held by Kairos, which also assumes all related obligations and liabilities while Enviro is released from them.
A separate novation with Tracon Pharmaceuticals, Inc. transfers Enviro’s rights and obligations under a license and supply agreement for TRC105 and CD105 technologies to Kairos. The company also announced it was selected to present Phase 2 clinical data on apalutamide plus carotuximab in advanced castration-resistant prostate cancer at the European Society for Medical Oncology Congress in Berlin.
Kairos Pharma, Ltd. filed an 8-K to share that it has issued a press release announcing positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The company is also hosting a virtual key opinion leader event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss and provide perspective on these data.
The press release is furnished as Exhibit 99.1 and the slide presentation for the event is furnished as Exhibit 99.2. This information is being furnished, not filed, under the Exchange Act, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. reported that it will host a premier key opinion leader (KOL) event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT. The event will focus on diverse perspectives regarding interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. The company furnished a related press release as Exhibit 99.1, noting that this information is being provided under an “Other Events” item and is treated as furnished rather than filed under the securities laws.
Kairos Pharma, Ltd. filed a report describing a recent corporate update. On September 3, 2025, the company issued a press release announcing its participation in the World Lung Cancer Conference in Barcelona, Spain. At this meeting, Principal Investigator Dr. Karen Reckamp is scheduled to present initial Phase 1 data for the company’s drug candidate ENV105 in non-small cell lung cancer.
The conference is taking place from September 6–9, 2025 at the Fira de Barcelona Gran Via. The press release with additional details is provided as Exhibit 99.1 to the report and is being furnished rather than filed, meaning it is not incorporated into the company’s other Securities Act or Exchange Act filings by default.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 884,938 shares of Kairos Pharma, Ltd. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities under an Investment Management Agreement. Neither Armistice Capital nor Mr. Boyd claim sole voting or sole dispositive power; both report 0 sole and 884,938 shared voting and dispositive powers. The filing states the shares are held in the ordinary course of business and not acquired to influence control. The Schedule 13G/A is jointly filed and signed by Steven Boyd as Managing Member.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing immunotherapy and cell therapy candidates. As of June 30, 2025, the company held $3,034 in cash and cash equivalents and reported a six-month net loss of $2,684. Operating expenses for the six months were $2,722, driven by $989 of R&D (including Phase 2 ENV105 prostate and Phase 1 ENV105 lung trials and a Phase 1 for KROS201) and $1,733 of general and administrative costs. Accumulated deficit was $11,499 and shareholders' equity was $5,997.
The company raised capital in 2025 via a January PIPE (net proceeds $3,058) and draws under a $30,000 Equity Line of Credit (ELOC), selling 3,510,000 ELOC shares for aggregate net proceeds of $3,903 as of the filing and an additional 3,000,000 ELOC shares for $3,693 in July 2025. Deferred offering costs totaled $1,692. Vendor advances, net, were $1,717 with significant amortization in the period. The company states current cash is expected to fund operations for at least 12 months, but continues to depend on future financings to execute its development plan.